Hypofractionated bladder RT with or without image guided adaptive planning (HYBRID) is a multicentre clinical trial investigating “Plan of the Day” (PoD) adaptive radiotherapy for bladder cancer. To ensure correct PoD selection a pre-accrual guidance and assessment module was developed as part of an image guided radiotherapy quality assurance (IGRT QA) credentialing programme. This study aimed to evaluate its feasibility and effectiveness across multiple recruiting centres.
Individuals from participating centres remotely accessed an image database in order to complete the PoD module. An assessment score of ≥83% was required in order to receive QA approval. A questionnaire was used to gather user feedback on the module. PoD decisions for the first patient at each recruiting centre were retrospectively reviewed for protocol adherence.
71 radiation therapists (RTTs) from 10 centres completed the PoD module. The median assessment score was 92% (Range: 58-100%) with 79% of RTTs passing the assessment on first attempt. All questionnaire respondents reported that the PoD module prepared them for plan selection. In 51/60 of on-trial treatments reviewed, the PoD selected by the centre agreed with QA reviewers.
The PoD QA module was successfully implemented in a multicentre trial and enabled pre-accrual assessment of protocol understanding. This increased operator confidence and resulted in appropriate PoD selection on-trial.
Clinical and translational radiation oncology. 2019 Jul 24*** epublish ***
Emma Patel, Yat Tsang, Angela Baker, Jenny Callender, Shaista Hafeez, Emma Hall, Vibeke Nordmark Hansen, Rebecca Lewis, Helen McNair, Elizabeth Miles, Robert Huddart
Radiotherapy Physics Department, University College London Hospitals NHS Foundation Trust, London, United Kingdom., National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, United Kingdom., Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., University of Liverpool, Liverpool, United Kingdom., Department of Radiotherapy and Imaging, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, London, United Kingdom., Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.